Thymosin Alpha-1 Profile

Last updated: June 13, 2026

TL;DR

Thymosin Alpha-1 (Tα1) is a 28-amino-acid immune-modulating peptide naturally produced by the thymus gland. It activates T-cells, dendritic cells, and natural killer cells, restoring immune balance in patients with viral infections, sepsis, and immunosuppression. Approved in over 30 countries (Italy as Zadaxin) as adjunct therapy for hepatitis B and C, and used off-label for chronic Lyme, chronic fatigue, and post-viral recovery. Dose: 1.6 mg subcutaneously 2-3x per week, 12 week cycles. The premier immune-restoration peptide.

What is Thymosin Alpha-1?

Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide first isolated from bovine thymus extract in 1972 by Allan Goldstein at Albert Einstein College of Medicine. The peptide sequence is conserved across mammals, including humans. In the body, the thymus produces Tα1 to instruct T-cell precursors how to recognize threats and mount appropriate immune responses. Production declines sharply with age – by 50 most humans produce roughly 25% of their childhood Tα1 levels.

How does Thymosin Alpha-1 work?

The peptide signals through Toll-like receptor 9 (TLR9) on dendritic cells and macrophages, triggering a cascade:

• Activates dendritic cells – antigen-presenting cells that direct T-cell responses
• Increases CD4+ helper T-cell production and maturation
• Enhances natural killer (NK) cell cytotoxic activity
• Boosts interleukin-12 and interferon-gamma signalling
• Reduces inflammatory IL-1, IL-6, and TNF-alpha when these are elevated

The net effect is immune restoration rather than immune stimulation. Tα1 increases T-cell activity in immunosuppressed patients but actually dampens overactive inflammatory responses in autoimmune or sepsis contexts. The dual nature is why it has been studied across infectious disease, cancer, autoimmunity, and post-viral syndromes.

What dose should you use?

Standard research protocols:

• Maintenance/general immune support: 1.6 mg subcutaneous, 2x per week (Monday/Thursday)
• Active viral infection: 1.6 mg subcutaneous, daily for 7-14 days
• Hepatitis C protocol: 1.6 mg 2x per week alongside interferon for 24-48 weeks
• Cycle length: 8-12 weeks on, 4-8 weeks off

Pharmaceutical Zadaxin dosing is 1.6 mg 2x weekly. Research peptide users typically follow the same dosing. Going above 3.2 mg per dose produces no additional benefit and increases injection-site reactions.

What conditions has it been studied for?

Major studied uses:

• Hepatitis B and C: approved in 30+ countries, increases interferon response rates
• Severe sepsis: meta-analysis showed reduced mortality in ICU patients
• HIV (as adjunct): maintains CD4+ counts during antiretroviral therapy
• Chronic Lyme disease: off-label, anecdotal evidence of immune function restoration
• Cancer adjunct: melanoma and lung cancer trials with mixed results
• Post-viral fatigue: long COVID and chronic fatigue syndrome – growing off-label use
• Vaccine response in elderly: improves antibody titers after influenza vaccination

The drug has the broadest immune-modulation evidence base of any peptide in commercial circulation. The catch: most studies are small, many are open-label, and large Phase 3 trials in the U.S. have been limited.

What are the side effects?

At standard 1.6 mg doses:

• Injection-site redness or tenderness (15-25% of doses)
• Transient flu-like symptoms (under 5%)
• Mild headache during first week (5-10%)
• No reported HPTA effects
• No reported organ toxicity in over 30 years of clinical use

The safety profile is exceptional. Long-term use in hepatitis patients has spanned 5+ years without significant adverse events. The peptide does not stimulate autoimmunity in studied populations – even though it boosts T-cell function, it does not increase autoimmune flare risk.

How does it compare to other immune peptides?

Tα1 vs the alternatives:

• Thymalin: cheaper, broader thymic extract, less specific mechanism
• Thymulin: zinc-dependent, narrower function
• BPC-157: gut and tissue healing, no direct immune signalling
• LL-37: antimicrobial peptide, different mechanism

Tα1 is the most evidence-backed peptide for immune restoration. Thymalin is the value alternative – similar broad effects, lower cost, less precise mechanism characterization.

How do you reconstitute Thymosin Alpha-1?

Standard reconstitution:

• 5 mg vial + 2.5 mL bacteriostatic water = 2 mg/mL
• 1.6 mg dose = 0.8 mL = 80 units on a 100-unit insulin syringe
• Alternative: 5 mg + 5 mL bacteriostatic water = 1 mg/mL, 1.6 mg = 1.6 mL (split into 2 injections)

Subcutaneous injection into abdominal fat or thigh. Rotate sites. Reconstituted Tα1 is stable refrigerated for 30 days. Lyophilized powder stable 18-24 months in cool dark storage. Our reconstitution guide covers the math.

How long until you notice effects?

Realistic timeline:

• Weeks 1-2: subtle – some users report mild flu-like symptoms as immune wakes up
• Weeks 3-4: fewer common colds, faster recovery from minor infections
• Weeks 5-8: improved energy, reduced inflammatory markers on bloodwork
• Weeks 9-12: peak benefit, CD4+ count improvements measurable

Tα1 is not a stimulant. The effect is restoration rather than addition – you feel like a healthy version of yourself, not a supercharged version.

Is Thymosin Alpha-1 legal in Canada?

Sold as a research peptide in Canada. Not Health Canada approved for human consumption, despite being approved in many countries as Zadaxin. WADA does not currently prohibit it in or out of competition. The compounded pharmacy market for off-label hepatitis and immune use exists in the U.S. but not formally in Canada.

Sources

• Goldstein AL, et al. Thymosin alpha 1: chemistry, mechanism of action and clinical applications. Ann N Y Acad Sci, 2007.
• Camerini R, Garaci E. Historical review of thymosin alpha 1 in infectious diseases. Expert Opin Biol Ther, 2015.
• Wu J, et al. The efficacy and safety of thymosin alpha-1 in severe sepsis: a meta-analysis. Crit Care, 2015.
• SciClone Pharmaceuticals Zadaxin prescribing information, 2024.